[Hit News] Global Eyes on ‘AAV Gene Therapy’… Domestic Development Active as WellFounded in September 2020, Aavatar Therapeutics focuses on designing and building a production platform for AAV gene therapy, and has pipelines for lysosomal storage disease (LSD) and hereditary hearing loss.

2024.11.24

[Smart Today] 50 Baby Unicorn Companies and 15 Potential Unicorn Companies Selected for 2024The Ministry of SMEs and Startups (Minister Oh Young-joo) announced on the 27th that it had selected 50 “baby unicorn” companies and 15 potential unicorn companies that have a high potential to grow into unicorn companies.

2024.06.28

[The Stock] Gene therapy emerging as a ‘dream drug’… Bio startups compete fiercely for developmentAavatar Therapeutics (CEO Seunghee Cho)’ is expanding its business by receiving 5 billion won in Series A investment from TS Investment, Shinhan Capital, Smilegate Investment, and Wonik Investment Partners in November of last year..

2024.01.17

[JoongAng Ilbo] Seunghee Cho, CEO of Aavatar Therapeutics, "Leading Gene Therapy with Engineering AVV Development"“We will contribute to patient health and health insurance by solving the root cause of diseases with drugs that work at the genetic level and quickly and economically providing customized drugs through precision medicine,” said CEO Cho.

2023.11.23

[The Bell] Gene Therapy CMO 'Aavatar Therapeutics' Series A ProcurementAavatar Therapeutics, a CMO for gene therapy based on a recombinant AAV platform, has completed Series A funding. It is expanding partnerships while securing AAV platform technology in just three years since its establishment.

2023.11.07

[Korea Economic Daily] Aavatar Therapeutics Attracts 5 Billion Won Series A InvestmentAavatar Therapeutics announced on the 7th that it had attracted 5 billion won in Series A investment. This investment, led by TS Investment, was participated by Shinhan Capital, Smilegate Investment, and Wonik Investment Partners.

2023.11.07

[Edaily] Seunghee Cho, CEO of Aavatar Therapeutics, “All-out effort to secure technology to produce ‘recombinant AAV’, a gene delivery vehicleCEO Cho emphasized, “AAV-based gene therapy is a promising alternative for treating rare diseases,” and “Only a few domestic bio ventures, such as Aavatar Therapeutics, possess AAV platform technology, and they are rare even worldwide.”

2023.03.23

[Dong-A Ilbo] Innovation Startup in Hongneung | Aavatar Therapeutics “Cure Rare Incurable Pediatric Diseases with Genes”CEO Cho Seung-hee says rare diseases can be cured by improving genetic defects using gene editing and amplification technology. About 80% of the 7,000 rare diseases are caused by genetic sequence mutations.

2022.05.19